4-chlorocarbonyloxy-benzoic acid benzyl ester

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-chlorocarbonyloxy-benzoic acid benzyl ester
• 英文别名: benzyl-(p-hydroxybenzoate) chloroformate；4-Chlorocarbonyloxy-benzoic acid benzyl ester；benzyl 4-carbonochloridoyloxybenzoate
• 化学式: C₁₅H₁₁ClO₄
• 分子量: 290.703
• InChiKey: XSNYZEXSXZOFGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chlorocarbonyloxy-benzoic acid benzyl ester 在 palladium on activated charcoal 、 氢气 作用下， 以 甲醇 为溶剂， 反应 0.84h， 生成
  参考文献：
  名称：

  Discovery of carbamate-based N-salicyloyl tryptamine derivatives as novel pleiotropic agents for the treatment of Alzheimer's disease

  摘要：

  DOI：

  10.1016/j.bioorg.2022.105993
• 作为产物：
  描述：

  对羟基苯甲酸 在 吡啶 、 碳酸氢钠 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 生成 4-chlorocarbonyloxy-benzoic acid benzyl ester
  参考文献：
  名称：

  Discovery of carbamate-based N-salicyloyl tryptamine derivatives as novel pleiotropic agents for the treatment of Alzheimer's disease

  摘要：

  DOI：

  10.1016/j.bioorg.2022.105993

文献信息

• Compounds for treating disorders where a decreased level of plasma FFA is desired
  申请人：——

  公开号：US20020082254A1

  公开（公告）日：2002-06-27

  The present invention relates to novel compounds, compositions containing them, and their use for treating medical disorders where a decreased level of plasma free fatty acids (FFA) is desired.

  这项发明涉及新化合物、含有这些化合物的组合物，以及它们用于治疗需要降低血浆游离脂肪酸（FFA）水平的医学疾病的用途。
• Compositions and methods for enhancing drug delivery across and into epithelial tissues
  申请人：CellGate, Inc.

  公开号：US06669951B2

  公开（公告）日：2003-12-30

  This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier. The compositions and methods employ a delivery enhancing transporter that has sufficient guanidino or amidino sidechain moieties to enhance delivery of a compound conjugated to the reagent across one or more layers of the tissue, compared to the non-conjugated compound. The delivery-enhancing polymers include, for example, poly-arginine molecules that are preferably between about 6 and 25 residues in length.

  这项发明提供了增强药物和其他药剂跨上皮组织传递的组合物和方法，包括皮肤、胃肠道、肺部上皮、眼部组织等。这些组合物和方法还适用于跨内皮组织传递，包括血脑屏障。这些组合物和方法利用一种传递增强转运体，其具有足够的瓜二胺或酰胺侧链基团，以增强与试剂结合的化合物跨组织的传递，相比未结合的化合物。传递增强聚合物包括例如，首选长度在6到25个残基之间的多精氨酸分子。
• Nitrogenous heterocyclic compound, preparation method, intermediate, composition and use
  申请人：SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.

  公开号：US10828305B2

  公开（公告）日：2020-11-10

  Disclosed are a nitrogenous heterocyclic compound, intermediates, a preparation method, a composition and use thereof. The nitrogenous heterocyclic compound in the present invention is as shown in formula I. The compound has a high inhibitory activity towards ErbB2 tyrosine kinase and a relatively good inhibitory activity towards human breast cancer BT-474 and human gastric cancer cell NCI-N87 which express ErbB2 at a high level, and at the same time has a relatively weak inhibitory activity towards EGFR kinase. Namely, the compound is a highly selective small-molecule inhibitor targeted at ErbB2, and hence it has a high degree of safety, and can effectively enlarge the safety window in the process of taking the drug.

  本发明公开了一种含氮杂环化合物、中间体、制备方法、组合物及其用途。本发明中的含氮杂环化合物如式 I 所示。该化合物对 ErbB2 酪氨酸激酶有较高的抑制活性，对高水平表达 ErbB2 的人乳腺癌 BT-474 和人胃癌细胞 NCI-N87 有较好的抑制活性，同时对表皮生长因子受体激酶的抑制活性相对较弱。也就是说，该化合物是一种针对 ErbB2 的高选择性小分子抑制剂，因此具有很高的安全性，可以有效地扩大用药过程中的安全窗口期。
• [EN] COMPOUNDS FOR TREATING DISORDERS WHERE A DECREASED LEVEL OF PLASMA FFA IS DESIRED<br/>[FR] COMPOSES DESTINES AU TRAITEMENT DE TROUBLES DANS LESQUELS UNE DIMINUTION DU NIVEAU D'AGL DU PLASMA EST VOULUE
  申请人：NOVO NORDISK AS

  公开号：WO2001087843A1

  公开（公告）日：2001-11-22

  The present invention relates to novel compounds of general formula (I), wherein A is a nitrogen containing ring systen attached through the nitrogen atom, compositions containing them, and their use for treating medical disorders where a decreased level of plasma free fatty acids (FFA) is desired.
• Discovery of carbamate-based N-salicyloyl tryptamine derivatives as novel pleiotropic agents for the treatment of Alzheimer's disease
  作者：Yuying Wang、Honghua Zhang、Dan Liu、Xuelin Li、Lin Long、Ying Peng、Fujian Qi、Yuqing Wang、Weifan Jiang、Zhen Wang

  DOI：10.1016/j.bioorg.2022.105993

  日期：2022.10